TEL AVIV, Israel and RALEIGH, N.C., March 18, 2021 /PRNewswire/ —
Financials:
Full year 2020 net revenues of approximately $64 million, with gross profit of approximately $27.5 million
Solid cash balance of approximately $100 million as of March 4, 2021
Planned commercial operational breakeven by the end of 2021
Commercial Highlights:
Talicia: Consistent month-over-month prescription growth despite pandemic conditions, with 52% new prescription growth in Q4/2020 compared to Q3/2020
Movantik: Market leadership position holding strong and well-positioned for further growth in 2021
R&D Highlights:
Two advanced programs at the forefront of global COVID-19 novel therapeutics development:
- Opaganib: Ongoing global Phase 2/3 study in hospitalized patients approximately two thirds enrolled, data expected Q2/2021; Positive U.S. Phase 2 data reported
- RHB-107: Ongoing U.S. Phase 2/3 study in symptomatic non-hospitalized patients
RHB-204: Ongoing Phase 3 study for pulmonary NTM disease as oral first-line treatment
Management to host webcast today, at 8:30 a.m. EDT
RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today reported its financial results and operational highlights for the year ended December 31, 2020.
Dror Ben-Asher, RedHill’s Chief Executive Officer, said: “2020 was a year that our team looks back on with a sense of immense achievement. While navigating the challenging conditions caused by the pandemic, we…
